Spiro azepane-oxazolidinones as Kv1.3 potassium channel blockers: WO2010066840

Research output: Contribution to journalArticlepeer-review

9 Scopus citations


This article evaluates a patent application from Solvay Pharmaceuticals, which claims spiro azepane-oxazolidinones as novel blockers of the voltage-gated potassium channel Kv1.3 for the treatment of diabetes, psoriasis, obesity, transplant rejection and T-cell mediated autoimmune diseases such as rheumatoid arthritis and MS. The patent describes a new chemotype of Kv1.3 blockers and thus illustrates the growing interest of the pharmaceutical industry in Kv1.3 as a target of immunosuppression and metabolic disorders. This article briefly summarizes the chemistry and biological data provided in the patent and then compares the new compounds to Kv1.3 blockers previously disclosed by both academia and pharmaceutical companies.

Original languageEnglish (US)
Pages (from-to)1759-1765
Number of pages7
JournalExpert Opinion on Therapeutic Patents
Issue number12
StatePublished - Dec 2010


  • diabetes
  • immunosuppression
  • Kv1.3
  • MS
  • potassium channel
  • spiro azepane-oxazolidinones

ASJC Scopus subject areas

  • Drug Discovery
  • Pharmacology


Dive into the research topics of 'Spiro azepane-oxazolidinones as Kv1.3 potassium channel blockers: WO2010066840'. Together they form a unique fingerprint.

Cite this